EGFR and metastatic colorectal cancer: The introduction of targeted therapies, especially monoclonal antibodies targeting epidermal growth factor receptor (EGFR), such as cetuximab, a human-mouse chimeric IgG1 antibody, in the treatment of patients with metastatic colorectal cancer (mCRC), has led to a consistent improvement in survival.